RS59050B1 - Farmaceutski preparati humanih rpe ćelija i njihova upotreba - Google Patents

Farmaceutski preparati humanih rpe ćelija i njihova upotreba

Info

Publication number
RS59050B1
RS59050B1 RS20190890A RSP20190890A RS59050B1 RS 59050 B1 RS59050 B1 RS 59050B1 RS 20190890 A RS20190890 A RS 20190890A RS P20190890 A RSP20190890 A RS P20190890A RS 59050 B1 RS59050 B1 RS 59050B1
Authority
RS
Serbia
Prior art keywords
cells
rpe
cell
rpe cells
average
Prior art date
Application number
RS20190890A
Other languages
English (en)
Serbian (sr)
Inventor
Roger Gay
Irina Klimanskaya
Robert Lanza
Original Assignee
Astellas Inst For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47470610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS59050(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Inst For Regenerative Medicine filed Critical Astellas Inst For Regenerative Medicine
Publication of RS59050B1 publication Critical patent/RS59050B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
RS20190890A 2011-11-14 2012-11-14 Farmaceutski preparati humanih rpe ćelija i njihova upotreba RS59050B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161559521P 2011-11-14 2011-11-14
US201261589741P 2012-01-23 2012-01-23
US201261724047P 2012-11-08 2012-11-08
EP12848968.9A EP2780022B2 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof
PCT/US2012/065091 WO2013074681A1 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof

Publications (1)

Publication Number Publication Date
RS59050B1 true RS59050B1 (sr) 2019-08-30

Family

ID=47470610

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190890A RS59050B1 (sr) 2011-11-14 2012-11-14 Farmaceutski preparati humanih rpe ćelija i njihova upotreba

Country Status (23)

Country Link
US (4) US20130195806A1 (enExample)
EP (2) EP3563860A1 (enExample)
JP (7) JP6506023B2 (enExample)
KR (1) KR102054904B1 (enExample)
CN (2) CN113786417A (enExample)
AU (5) AU2012340020A1 (enExample)
CA (2) CA2855941A1 (enExample)
CY (1) CY1121819T1 (enExample)
DK (1) DK2780022T4 (enExample)
ES (1) ES2734453T3 (enExample)
FI (1) FI2780022T4 (enExample)
GB (1) GB2496969A (enExample)
HK (1) HK1202456A1 (enExample)
HR (1) HRP20191110T1 (enExample)
HU (1) HUE044778T2 (enExample)
IL (5) IL287381B2 (enExample)
LT (1) LT2780022T (enExample)
PL (1) PL2780022T3 (enExample)
PT (1) PT2780022T (enExample)
RS (1) RS59050B1 (enExample)
SI (1) SI2780022T1 (enExample)
TW (5) TW202434266A (enExample)
WO (1) WO2013074681A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
SG188122A1 (en) 2004-01-23 2013-03-28 Advanced Cell Tech Inc Improved modalities for the treatment of degenerative diseases of the retina
ES2764473T3 (es) 2007-10-12 2020-06-03 Astellas Inst For Regenerative Medicine Métodos mejorados para producir células RPE y composiciones de células RPE
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
US10852069B2 (en) 2010-05-04 2020-12-01 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a fractal heat sink
ES2874953T3 (es) 2010-07-23 2021-11-05 Astellas Inst For Regenerative Medicine Métodos para la detección de subpoblaciones raras de células y composiciones muy purificadas de células
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
AU2012314514B2 (en) 2011-09-26 2018-03-15 Qiagen Gmbh Stabilisation and isolation of extracellular nucleic acids
ES2574956T3 (es) 2011-09-26 2016-06-23 Preanalytix Gmbh Estabilización y aislamiento de ácidos nucleicos extracelulares
CA2855941A1 (en) * 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
CA2884915C (en) 2012-09-25 2022-05-17 Qiagen Gmbh Stabilisation of biological samples
US20150368713A1 (en) 2013-02-01 2015-12-24 THE UNITED STATES OF AMERICAN, as represented by the Secretary, Department of Health and Human Serv METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
WO2014146780A1 (en) 2013-03-18 2014-09-25 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
EP3447141B1 (en) 2013-03-18 2020-08-05 PreAnalytiX GmbH Stabilisation of biological samples
RU2704984C1 (ru) 2013-11-27 2019-11-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Применение ламинина в культуре клеток эндотелия роговицы
EP3080248A1 (en) 2013-12-11 2016-10-19 Pfizer Limited Method for producing retinal pigment epithelial cells
CN106102766A (zh) * 2014-01-22 2016-11-09 皮埃尔与玛丽·居里大学 - 巴黎第六大学 用于治疗视网膜炎症的试剂
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
US20160374330A1 (en) * 2014-03-18 2016-12-29 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
WO2015175504A1 (en) * 2014-05-12 2015-11-19 The Johns Hopkins University Differentiation of human pluripotent stem cells into retinal pigment epithelium using hif1 inhibitors
US10457915B2 (en) 2014-05-15 2019-10-29 International Stem Cell Corporation Chemical differentiation of pluripotentstem cells into retinal epithelial cells
US10597633B2 (en) 2014-05-16 2020-03-24 Koninklijke Nederlandse Akademie Van Wetenschappen Culture method for organoids
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160095307A1 (en) 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
WO2016067629A1 (ja) * 2014-10-31 2016-05-06 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
CN113559246A (zh) * 2014-10-31 2021-10-29 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
KR102728629B1 (ko) * 2014-12-18 2024-11-12 쏘흐본느 유니베흐시테 망막 변성의 치료를 위한 otx2를 과발현하는 형질전환 rpe 세포
MX2017008737A (es) * 2014-12-30 2018-01-25 Cell Cure Neurosciences Ltd Poblaciones de celulas rpe y metodos para generar las mismas.
EA201791518A1 (ru) * 2014-12-30 2017-10-31 Селл Кьюр Нейросайансес Лтд. Способы лечения заболеваний сетчатки
US20180011092A1 (en) 2014-12-30 2018-01-11 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
EP4343331A3 (en) * 2015-03-23 2024-06-19 Astellas Institute for Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
CN105013010B (zh) * 2015-07-07 2018-01-12 中山大学中山眼科中心 一种辅助iPS‑RPE移植的层粘连蛋白膜
PL3331994T3 (pl) 2015-08-05 2023-01-30 Cell Cure Neurosciences Ltd. Wytwarzanie komórek nabłonka barwnikowego siatkówki
AU2016308818B2 (en) 2015-08-18 2022-04-21 Astellas Institute For Regenerative Medicine Clinical formulations
AU2016318774B2 (en) * 2015-09-08 2022-08-18 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
CA3005694A1 (en) 2015-11-20 2017-05-26 Qiagen Gmbh Method of preparing sterilized compositions for stabilization of extracellular nucleic acids
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
CN106420809B (zh) * 2016-08-31 2017-08-08 浙江济民制药股份有限公司 一种眼科手术灌注液
EP3555266B1 (en) * 2016-12-13 2023-11-15 The United States of America, as Represented by The Secretary, Department of Health and Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US11076984B2 (en) * 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
CN110913874A (zh) * 2017-03-16 2020-03-24 谱系细胞疗法公司 用于测量视网膜疾病疗法的疗效的方法
AU2018263853A1 (en) * 2017-05-01 2019-11-14 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treating ocular pathologies
SG11202005795TA (en) * 2017-12-29 2020-07-29 Cell Cure Neurosciences Ltd Retinal pigment epithelium cell compositions
EP4371535A3 (en) 2018-02-22 2024-08-14 Alcon Inc. Ocular implant
BR112020017872A2 (pt) * 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
KR20210095885A (ko) * 2018-11-19 2021-08-03 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 생분해성 조직 대체 임플란트 및 그의 용도
JP7590968B2 (ja) * 2018-12-05 2024-11-27 アビオナ・セラピュ―ティクス・インコーポレイテッド 遺伝子送達のための組み換えアデノ随伴ウイルスベクター
JP7701879B2 (ja) * 2019-05-28 2025-07-02 エフ． ホフマン－ラ ロシュ アーゲー 単球前駆細胞を生成するための方法
KR102198942B1 (ko) * 2019-07-02 2021-01-05 의료법인 성광의료재단 Pedf를 발현하거나 모세포에 비하여 pedf를 과발현하도록 유전적으로 조작된 중간엽 줄기세포
WO2021034784A1 (en) 2019-08-16 2021-02-25 Poltorak Technologies, LLC Device and method for medical diagnostics
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022005134A (es) 2019-10-30 2022-05-30 Astellas Inst For Regenerative Medicine Metodos para producir celulas del epitelio pigmentario retiniano.
CA3161672A1 (en) * 2019-11-22 2021-05-27 Sigilon Therapeutics, Inc. Monoclonal cell lines expressing an exogenous substance and uses thereof
KR20220130125A (ko) 2020-01-21 2022-09-26 다케다 야쿠힌 고교 가부시키가이샤 동결보존 세포의 조성물 및 방법
KR20220150906A (ko) * 2020-02-07 2022-11-11 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 신경변성의 발병 지연 또는 치료를 위한 대사체의 재프로그래밍
TW202216158A (zh) * 2020-07-10 2022-05-01 國立研究開發法人理化學研究所 網膜色素上皮細胞之移植用存活促進劑
CN112544612A (zh) * 2020-12-18 2021-03-26 江苏艾尔康生物医药科技有限公司 冻存液及其在rpe细胞冻存中的应用
CN112834411B (zh) * 2021-01-07 2022-05-27 上海交通大学 应用于质谱流式技术的金属纳米探针及制备方法和应用
CN112926116B (zh) * 2021-03-01 2023-02-17 哈尔滨工业大学 一种基于虚拟现实的体育馆火灾疏散行为数据收集系统及其收集方法
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
WO2023149420A1 (ja) * 2022-02-01 2023-08-10 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
CN114561356B (zh) * 2022-03-09 2022-09-13 北京呈诺医学科技有限公司 影响细胞因子分泌的方法及应用
US20250188412A1 (en) * 2022-03-16 2025-06-12 Sumitomo Pharma Co., Ltd. Transplantation medium
WO2024218311A1 (fr) * 2023-04-21 2024-10-24 Pulsesight Therapeutics Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
WO2024233368A1 (en) * 2023-05-05 2024-11-14 The Regents Of The University Of California Retinal pigment epithelium cell therapy
CN117625536B (zh) * 2024-01-26 2024-04-30 中国人民解放军总医院第三医学中心 一种人视网膜色素上皮细胞的纯化、培养方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138205A (en) 1975-12-15 1979-02-06 Hydro Pulse Corporation Movable stator walls permitting access to tubing in peristaltic pump
US5610753A (en) 1991-12-12 1997-03-11 Eastman Kodak Company Optical design of laser scanner to reduce thermal sensitivity
GB9608145D0 (en) * 1996-04-19 1996-06-26 British Tech Group Wound healing
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US5998423A (en) 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
AU9040098A (en) 1997-09-10 1999-03-29 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
WO1999034834A1 (en) * 1998-01-02 1999-07-15 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6576422B1 (en) * 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20020192738A1 (en) * 2001-04-27 2002-12-19 Janice Brissette Tyrosinase assay
CA2455499C (en) * 2001-08-08 2011-06-21 The Trustees Of The University Of Pennsylvania Method for purification of viral vectors having proteins which bind sialic acid
WO2003046141A2 (en) 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
WO2003060083A2 (en) 2002-01-15 2003-07-24 Advanced Cell Technology, Inc. Cloning b and t lymphocytes
US20040091936A1 (en) 2002-05-24 2004-05-13 Michael West Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
US7803750B2 (en) 2002-07-29 2010-09-28 Duke University Method of modulating melanin production
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
SG188122A1 (en) * 2004-01-23 2013-03-28 Advanced Cell Tech Inc Improved modalities for the treatment of degenerative diseases of the retina
US7309487B2 (en) * 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
ZA200901914B (en) * 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
ES2764473T3 (es) * 2007-10-12 2020-06-03 Astellas Inst For Regenerative Medicine Métodos mejorados para producir células RPE y composiciones de células RPE
GB0806746D0 (en) 2008-04-14 2008-05-14 Ucl Business Plc Membrane
US9173862B2 (en) * 2008-04-18 2015-11-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
WO2011063005A2 (en) * 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
ES2874953T3 (es) * 2010-07-23 2021-11-05 Astellas Inst For Regenerative Medicine Métodos para la detección de subpoblaciones raras de células y composiciones muy purificadas de células
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US9487752B2 (en) 2011-03-30 2016-11-08 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
EP2702135B1 (en) * 2011-04-29 2019-04-17 University of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
CA2855941A1 (en) * 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
PT3189135T (pt) * 2014-09-05 2021-08-19 Astellas Inst For Regenerative Medicine Células ganclionares retinianas e seus progenitores

Also Published As

Publication number Publication date
FI2780022T4 (fi) 2023-07-06
IL232600B (en) 2020-03-31
WO2013074681A9 (en) 2013-11-28
JP2022130370A (ja) 2022-09-06
JP2021113193A (ja) 2021-08-05
HUE044778T2 (hu) 2019-11-28
JP7404441B2 (ja) 2023-12-25
JP2025161815A (ja) 2025-10-24
IL287381A (en) 2021-12-01
JP2014533289A (ja) 2014-12-11
JP2019189614A (ja) 2019-10-31
DK2780022T3 (da) 2019-07-15
ES2734453T3 (es) 2019-12-10
US20200405767A1 (en) 2020-12-31
LT2780022T (lt) 2019-07-10
KR102054904B1 (ko) 2019-12-11
TW201333200A (zh) 2013-08-16
TWI655286B (zh) 2019-04-01
GB2496969A (en) 2013-05-29
AU2017225146C1 (en) 2019-08-22
AU2021204719B2 (en) 2024-11-21
IL308205B1 (en) 2025-06-01
IL287381B2 (en) 2024-04-01
JP7716463B2 (ja) 2025-07-31
EP2780022A4 (en) 2015-08-05
HRP20191110T1 (hr) 2019-09-20
WO2013074681A1 (en) 2013-05-23
EP2780022A1 (en) 2014-09-24
CN104080464A (zh) 2014-10-01
TW202434266A (zh) 2024-09-01
IL273107B (en) 2021-12-01
EP2780022B1 (en) 2019-06-05
IL308205A (en) 2024-01-01
PL2780022T3 (pl) 2019-11-29
GB201220511D0 (en) 2012-12-26
EP3563860A1 (en) 2019-11-06
JP6563996B2 (ja) 2019-08-21
TWI719277B (zh) 2021-02-21
EP2780022B2 (en) 2022-09-07
JP6899865B2 (ja) 2021-07-07
PT2780022T (pt) 2019-07-16
TW202120107A (zh) 2021-06-01
CN113786417A (zh) 2021-12-14
US20250134932A1 (en) 2025-05-01
US20130195806A1 (en) 2013-08-01
JP6506023B2 (ja) 2019-04-24
TW201828960A (zh) 2018-08-16
IL308205B2 (en) 2025-10-01
CY1121819T1 (el) 2020-07-31
AU2017225146B2 (en) 2019-01-17
IL287381B1 (en) 2023-12-01
DK2780022T4 (da) 2024-09-09
AU2019201201B2 (en) 2021-04-08
CA3178098A1 (en) 2013-05-23
KR20140096368A (ko) 2014-08-05
JP2024037864A (ja) 2024-03-19
AU2012340020A1 (en) 2014-07-03
AU2021204719A1 (en) 2021-08-05
IL232600A0 (en) 2014-06-30
CA2855941A1 (en) 2013-05-23
TWI785403B (zh) 2022-12-01
SI2780022T1 (sl) 2019-09-30
AU2019201201A1 (en) 2019-03-14
JP2018048144A (ja) 2018-03-29
AU2017225146A1 (en) 2017-10-05
TWI842079B (zh) 2024-05-11
AU2025201277A1 (en) 2025-03-13
JP7081016B2 (ja) 2022-06-06
TW202317157A (zh) 2023-05-01
IL320536A (en) 2025-06-01
IL273107A (en) 2020-04-30
HK1202456A1 (en) 2015-10-02
US20150366915A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
JP7716463B2 (ja) ヒトｒｐｅ細胞医薬品およびその使用
HK40064545A (en) Pharmaceutical preparations of human rpe cells and uses thereof
HK40015631A (en) Pharmaceutical preparations of human rpe cells and uses thereof